La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

PharmaSGP Holding Bilan de santé

Santé financière contrôle des critères 5/6

PharmaSGP Holding possède un total de capitaux propres de €44.7M et une dette totale de €73.2M, ce qui porte son ratio d'endettement à 163.9%. Son actif total et son passif total sont €140.9M et de €96.3M. L'EBIT de PharmaSGP Holding est €26.3M ce qui fait que son ratio de couverture des intérêts 7.4. Elle dispose de liquidités et de placements à court terme de €46.3M.

Informations clés

163.9%

Ratio d'endettement

€73.21m

Dette

Ratio de couverture des intérêts	7.4x
Argent liquide	€46.27m
Fonds propres	€44.67m
Total du passif	€96.26m
Total des actifs	€140.93m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de PSG ( €73.9M ) dépassent ses passifs à court terme ( €29.2M ).

Passif à long terme: Les actifs à court terme de PSG ( €73.9M ) dépassent ses passifs à long terme ( €67.1M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de PSG ( 60.3% ) est considéré comme élevé.

Réduire la dette: PSG avait des capitaux propres négatifs il y a 5 ans, mais ils sont désormais positifs et se sont donc améliorés.

Couverture de la dette: La dette de PSG est bien couverte par le flux de trésorerie opérationnel ( 37.8% ).

Couverture des intérêts: Les paiements d'intérêts de PSG sur sa dette sont bien couverts par l'EBIT ( 7.4 x couverture).

PharmaSGP Holding Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Price target increased by 9.2% to €38.75

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Consensus EPS estimates increase by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

Analysts lower EPS estimates to €0.95

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

New 90-day low: €19.76

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Market pulls back on stock over the past week

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Analysts lower EPS estimates to €1.13

New 90-day low: €27.00

New 90-day low: €28.75

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines